Order Article Reprints

Gristina V, Barraco N, La Mantia M, Castellana L, Insalaco L, Bono M, Perez A, Sardo D, Inguglia S, Iacono F, et al. Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study. Cancers. 2022; 14(23):6013. https://doi.org/10.3390/cancers14236013

Gristina, Valerio, Nadia Barraco, Maria La Mantia, Luisa Castellana, Lavinia Insalaco, Marco Bono, Alessandro Perez, Delia Sardo, Sara Inguglia, Federica Iacono, and et al. 2022. "Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study" Cancers 14, no. 23: 6013. https://doi.org/10.3390/cancers14236013

Gristina, V., Barraco, N., La Mantia, M., Castellana, L., Insalaco, L., Bono, M., Perez, A., Sardo, D., Inguglia, S., Iacono, F., Cutaia, S., Bazan Russo, T. D., Francini, E., Incorvaia, L., Badalamenti, G., Russo, A., Galvano, A., & Bazan, V. (2022). Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study. Cancers, 14(23), 6013. https://doi.org/10.3390/cancers14236013